Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ONCO.ST
- Price
- 1.31
- Stock movement down
- -0.26 (-5.44%)
- Company name
- Oncopeptides AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.00B
- Ent value
- 937.24M
- Price/Sales
- 37.08
- Price/Book
- 7.40
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -22.36%
- 1 year return
- 126.01%
- 3 year return
- -46.30%
- 5 year return
- -43.78%
- 10 year return
- -
Last updated: 2025-09-17
DIVIDENDS
ONCO.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 37.08 |
| Price to Book | 7.40 |
| EV to Sales | 34.62 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 224.12M |
| EPS (TTM) | -1.21 |
| FCF per share (TTM) | -1.05 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 27.07M |
| Gross profit (TTM) | 24.35M |
| Operating income (TTM) | -282.78M |
| Net income (TTM) | -282.39M |
| EPS (TTM) | -1.21 |
| EPS (1y forward) | -0.65 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 89.97% |
| Operating margin (TTM) | -1044.59% |
| Profit margin (TTM) | -1043.15% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 250.01M |
| Net receivables | 34.82M |
| Total current assets | 289.35M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 319.21M |
| Accounts payable | 12.10M |
| Short/Current long term debt | 117.16M |
| Total current liabilities | 46.27M |
| Total liabilities | 183.55M |
| Shareholder's equity | 135.66M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -244.47M |
| Capital expenditures (TTM) | 116.00K |
| Free cash flow (TTM) | -244.58M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -208.17% |
| Return on Assets | -88.47% |
| Return on Invested Capital | -111.70% |
| Cash Return on Invested Capital | -96.74% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.73 |
| Daily high | 4.73 |
| Daily low | 4.44 |
| Daily Volume | 5.20M |
| All-time high | 131.08 |
| 1y analyst estimate | 2.43 |
| Beta | -0.36 |
| EPS (TTM) | -1.21 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 5 Nov 2025 |
Downside potential
Loading...
Downside potential data
| ONCO.ST | S&P500 | |
| Current price drop from All-time high | -96.58% | -1.06% |
| Highest price drop | -99.12% | -56.47% |
| Date of highest drop | 23 Jan 2025 | 9 Mar 2009 |
| Avg drop from high | -59.34% | -10.99% |
| Avg time to new high | 44 days | 12 days |
| Max time to new high | 1789 days | 1805 days |
COMPANY DETAILS
Marketcap
1.00B
Marketcap category
Small-cap
Description
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for glioblastoma and hematological or solid tumors. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
Employees
79
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Oncopeptides AB reports significant sales growth and strategic progress, but faces ongoing financial hurdles and partnership delays.
August 22, 2025
Oncopeptides AB (FRA:OND) reports significant sales growth and key achievements, while navigating currency headwinds and market access challenges.
May 16, 2025
Oncopeptides AB (FRA:OND) reports a 35% increase in European sales and advances in key markets, despite facing challenges in France and Norway.
February 28, 2025
Oncopeptides AB (STU:OND) reports increased revenue and cost efficiency, while navigating market challenges and focusing on key European markets.
November 9, 2024